Drawing for HEDTUMSO

USPTO serial 90860790

HEDTUMSO

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
NADEAU, MADELINE JEAN
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with HEDTUMSO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Marilyn F. Kelly

Marilyn F. Kelly BRISTOL-MYERS SQUIBB COMPANYP.O. BOX 4000TRADEMARK DEPT., MAILSTOP D.4243PRINCETON, NJ 08648-4000

Goods and services

ClassDescriptionStatusFirst use
005pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical and biological preparations for human use for immunotherapy, namely t cell therapy; pharmaceutical preparations for human use, namely, stem cells for medical use; pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodiesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Apr 20, 2026MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Apr 20, 2026ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 15, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 29, 2025EX5GSOU EXTENSION 5 GRANTED—
Aug 26, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 25, 2025EXT5SOU EXTENSION 5 FILED—
Mar 11, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 10, 2025EX4GSOU EXTENSION 4 GRANTED—
Mar 10, 2025EXT4SOU EXTENSION 4 FILED—
Mar 10, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 27, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 27, 2024EX3GSOU EXTENSION 3 GRANTED—
Aug 27, 2024EXT3SOU EXTENSION 3 FILED—
Aug 27, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 9, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 7, 2024EX2GSOU EXTENSION 2 GRANTED—
Feb 7, 2024EXT2SOU EXTENSION 2 FILED—
Feb 7, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 8, 2023IULNITU LETTER MAILED, NO RESPONSE REQUIRED—
Sep 8, 2023AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Aug 31, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 29, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 29, 2023EX1GSOU EXTENSION 1 GRANTED—
Aug 29, 2023EXT1SOU EXTENSION 1 FILED—
Aug 29, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 2, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Aug 2, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Aug 2, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Mar 14, 2023NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jan 17, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 17, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 28, 2022NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 12, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 8, 2022XAECEXAMINER'S AMENDMENT ENTERED—
Dec 8, 2022GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Dec 8, 2022GNEAEXAMINERS AMENDMENT E-MAILED—
Dec 8, 2022CNEAEXAMINERS AMENDMENT -WRITTEN—
Oct 25, 2022TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 25, 2022CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 25, 2022TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 26, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 26, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 26, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 19, 2022DOCKASSIGNED TO EXAMINER—
Sep 28, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 5, 2021NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance